search
Back to results

C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema

Primary Purpose

Angioedema

Status
Completed
Phase
Phase 2
Locations
Netherlands
Study Type
Interventional
Intervention
C1 inhibitor concentrate (C1-esteraseremmer-N)
Sponsored by
Prothya Biosolutions
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional prevention trial for Angioedema focused on measuring MeSH: angioneurotic edema, complement 1 inactivators, Hereditary Angioedema Type I or II, Acquired Angioedema

Eligibility Criteria

16 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Inclusion criteria for hereditary angioedema patients: Established diagnosis of hereditary angioedema type I or II: markedly decreased C1 inhibitor activity; decreased (type I), normal or elevated (type II) level of C1 inhibitor antigen; decreased level of C4. Patients already using C1 inhibitor concentrate for prophylaxis of angioedema attacks. Age ≥ 16 years Signed informed consent by patient and patient's legal representative if under 18 years old Inclusion criteria for acquired angioedema patients: Established diagnosis of acquired angioedema: recurrent attacks of angioedema without urticaria; no family history; decreased functional C1 inhibitor; decreased level of C4. Autoantibodies to C1 inhibitor or decreased C1q or onset after the third decade of life. Age ≥ 16 years Patient already using C1 inhibitor concentrate for prophylaxis of angioedema attacks Signed informed consent by patient and patient's legal representative if under 18 years old Exclusion Criteria: Exclusion criteria for hereditary angioedema patients: Use of angioedema prophylactic medication during the study, other than C1-esteraseremmer-N. Change in oral contraceptives starting from the last two months before the start of the trial until the end of the study period. Presence of clinically relevant C1 inhibitor auto antibodies Participation in another pharmaceutical clinical study, which can interfere with this study, in the last 3 months prior to the study, other than in part A of this protocol. Usage of heparin starting from the last two days prior to the study until the end of the study period. B-cell malignancy Pregnancy or lactation History of allergic reaction to C1 inhibitor concentrate or other blood products Exclusion criteria for acquired angioedema patients: Participation in another pharmaceutical clinical study, which can interfere with this study, in the last 3 months prior to the study Usage of heparin within the last two days prior to the study Pregnancy or lactation History of allergic reaction to C1 inhibitor concentrate or other blood products

Sites / Locations

  • Academic Medical Centre

Outcomes

Primary Outcome Measures

The primary objective in this clinical study is to evaluate the prevention of angioedema attacks in patients prophylactically treated with C1-esteraseremmer-N.

Secondary Outcome Measures

The secondary objective of this study is to evaluate the safety and clinical activity of C1-esteraseremmer-N.

Full Information

First Posted
July 29, 2005
Last Updated
May 1, 2009
Sponsor
Prothya Biosolutions
search

1. Study Identification

Unique Protocol Identification Number
NCT00125541
Brief Title
C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema
Official Title
Pharmacokinetics, Clinical Efficacy and Safety of C1 Inhibitor Concentrate (C1-Esteraseremmer-N) for the Treatment of Hereditary (and Acquired) Angioedema
Study Type
Interventional

2. Study Status

Record Verification Date
May 2009
Overall Recruitment Status
Completed
Study Start Date
November 2006 (undefined)
Primary Completion Date
April 2008 (Actual)
Study Completion Date
May 2008 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Prothya Biosolutions

4. Oversight

5. Study Description

Brief Summary
A multicentre study to investigate the pharmacokinetics, clinical efficacy and safety of nanofiltered Cetor® (called C1-esteraseremmer-N during the development phase) for the treatment of hereditary angioedema (HAE) will be performed. This study (KB2003.01) consists of three parts: Part A - pharmacokinetics (phase II); Part B - treatment of attacks of angioedema (phase III); and Part C - prophylactic use of C1 inhibitor (phase III). Parts B + C will provide data on the efficacy of C1-esteraseremmer-N. The changes within the manufacturing process of C1-esteraseremmer-N, compared to Cetor® nanofiltration and omission of hepatitis B immunoglobulin, most likely will not affect tolerability. The nanofiltration will provide more safety regarding viruses. In part C of the study, a number of HAE patients will be treated prophylactically with open-label C1-esteraseremmer-N for a period of 16 weeks. The number of attacks occurring will be compared with historical data. If possible, also some patients treated prophylactically with C1 inhibitor for acquired angioedema will be included.
Detailed Description
A multicentre study to investigate the pharmacokinetics, clinical efficacy and safety of nanofiltered Cetor® (called C1-esteraseremmer-N during the development phase) for the treatment of hereditary angioedema (HAE) will be performed. This study (KB2003.01) consists of three parts: Part A - pharmacokinetics (phase II); Part B - treatment of attacks of angioedema (phase III); and Part C - prophylactic use of C1 inhibitor (phase III). Parts B + C will provide data on the efficacy of C1-esteraseremmer-N. The changes within the manufacturing process of C1-esteraseremmer-N, compared to Cetor® nanofiltration and omission of hepatitis B immunoglobulin, most likely will not affect tolerability. The nanofiltration will provide more safety regarding viruses. In part C of the study, a number of HAE patients will be treated prophylactically with open-label C1-esteraseremmer-N for a period of 16 weeks. The number of attacks occurring will be compared with historical data. If possible, also some patients treated prophylactically with C1 inhibitor for acquired angioedema will be included.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Angioedema
Keywords
MeSH: angioneurotic edema, complement 1 inactivators, Hereditary Angioedema Type I or II, Acquired Angioedema

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2, Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
6 (Anticipated)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
C1 inhibitor concentrate (C1-esteraseremmer-N)
Intervention Description
every 5-7 days
Primary Outcome Measure Information:
Title
The primary objective in this clinical study is to evaluate the prevention of angioedema attacks in patients prophylactically treated with C1-esteraseremmer-N.
Time Frame
16 weeks
Secondary Outcome Measure Information:
Title
The secondary objective of this study is to evaluate the safety and clinical activity of C1-esteraseremmer-N.
Time Frame
16 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Inclusion criteria for hereditary angioedema patients: Established diagnosis of hereditary angioedema type I or II: markedly decreased C1 inhibitor activity; decreased (type I), normal or elevated (type II) level of C1 inhibitor antigen; decreased level of C4. Patients already using C1 inhibitor concentrate for prophylaxis of angioedema attacks. Age ≥ 16 years Signed informed consent by patient and patient's legal representative if under 18 years old Inclusion criteria for acquired angioedema patients: Established diagnosis of acquired angioedema: recurrent attacks of angioedema without urticaria; no family history; decreased functional C1 inhibitor; decreased level of C4. Autoantibodies to C1 inhibitor or decreased C1q or onset after the third decade of life. Age ≥ 16 years Patient already using C1 inhibitor concentrate for prophylaxis of angioedema attacks Signed informed consent by patient and patient's legal representative if under 18 years old Exclusion Criteria: Exclusion criteria for hereditary angioedema patients: Use of angioedema prophylactic medication during the study, other than C1-esteraseremmer-N. Change in oral contraceptives starting from the last two months before the start of the trial until the end of the study period. Presence of clinically relevant C1 inhibitor auto antibodies Participation in another pharmaceutical clinical study, which can interfere with this study, in the last 3 months prior to the study, other than in part A of this protocol. Usage of heparin starting from the last two days prior to the study until the end of the study period. B-cell malignancy Pregnancy or lactation History of allergic reaction to C1 inhibitor concentrate or other blood products Exclusion criteria for acquired angioedema patients: Participation in another pharmaceutical clinical study, which can interfere with this study, in the last 3 months prior to the study Usage of heparin within the last two days prior to the study Pregnancy or lactation History of allergic reaction to C1 inhibitor concentrate or other blood products
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
M. M. Levi, Prof. Dr.
Organizational Affiliation
Academic Medical Centre Amsterdam
Official's Role
Principal Investigator
Facility Information:
Facility Name
Academic Medical Centre
City
Amsterdam
ZIP/Postal Code
1100 DD
Country
Netherlands

12. IPD Sharing Statement

Learn more about this trial

C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema

We'll reach out to this number within 24 hrs